Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 1,177 shares, an increase of 97.5% from the May 14th total of 596 shares. Based on an average daily volume of 10,593 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on AAPG. Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. B. Riley Financial initiated coverage on Ascentage Pharma Group International in a report on Wednesday, June 10th. They set a “buy” rating and a $45.00 target price on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 target price on the stock. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Finally, BTIG Research reiterated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. According to MarketBeat.com, Ascentage Pharma Group International currently has an average rating of “Buy” and an average target price of $46.43.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently modified their holdings of AAPG. Citadel Advisors LLC bought a new position in Ascentage Pharma Group International in the 3rd quarter worth $383,000. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International in the 2nd quarter worth $391,000. XY Capital Ltd raised its holdings in Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the period. Finally, UBS Group AG raised its holdings in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the period.

Ascentage Pharma Group International Stock Down 1.5%

NASDAQ AAPG opened at $17.34 on Tuesday. The business’s fifty day moving average price is $21.90 and its 200-day moving average price is $24.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. Ascentage Pharma Group International has a 1-year low of $16.92 and a 1-year high of $48.45.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The firm had revenue of $24.72 million during the quarter. As a group, research analysts anticipate that Ascentage Pharma Group International will post -0.96 EPS for the current year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.